Cutaneous CpG adjuvant conditioning to enhance vaccine responses

Douglas A. Carlow, Jacqueline C.Y. Lai, Tobias R. Kollmann, Manish Sadarangani, Jan P. Dutz

Research output: Contribution to journalArticlepeer-review


Adjuvant activity of the Toll receptor 9 agonist CpG 1826 was compared when given subcutaneously (s.c.) together with ovalbumin (s.c.[CpG + Ova]), or when given by either s.c. or intradermally (i.d.) routes two days prior to s.c. ovalbumin. Frequencies of CD8 + effector (TEFF) and central memory (TCM) T cells along with total IgG, IgG2c, and IgG1 titres were measured to ascertain how timing and location of CpG conditioning influenced vaccination outcome. Prior treatment with CpG enhanced TEFF, TCM, as well as total IgG responses. TEFF and TCM responses were greatest when CpG was given intradermally and prior to s.c. ovalbumin, conditions that eliminated the fraction of TCM ‘non-responders’ observed after s.c.[CpG + Ova] vaccination. IgG responses were polarized toward IgG2c after early s.c. CpG but toward IgG1 after early i.d. CpG. Separating CpG adjuvant and antigen application in time and space can improve vaccination outcome.

Original languageEnglish
Pages (from-to)1385-1389
Number of pages5
Issue number10
Publication statusPublished - 1 Mar 2022


Dive into the research topics of 'Cutaneous CpG adjuvant conditioning to enhance vaccine responses'. Together they form a unique fingerprint.

Cite this